Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SQLE drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SQLE (Truncated Catalytic Domain, aa 100-574) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for cell-free enzymatic screening. |
View SQLE Products |
| Gene Delivery | SQLE Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to evaluate intracellular cholesterol synthesis. |
View SQLE Products |
| Benchmark Ab | Anti-SQLE Recombinant Antibody Sequence verified recombinant antibody for Western Blot, IHC, and target validation. |
View SQLE Products |
| Validator | SQLE siRNA Set For knockdown verification in tumor and metabolic cell models. |
View SQLE Products |
| Related Target A | HMGCR The primary rate-limiting enzyme in cholesterol synthesis; crucial for combination study and selectivity screening. |
View HMGCR Products |
| Related Target B | SREBP2 Master transcription factor regulating SQLE and cholesterol homeostasis; ideal for downstream pathway analysis. |
View SREBP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER-membrane localization limits full-length protein solubility | Truncated catalytic domain (aa 100-574) designed for high solubility and stability in cell-free assays |
| Selectivity profiling against other monooxygenases | Highly purified recombinant target panels verified by Mass Spectrometry to prevent off-target false positives |
| Lack of Controls | Clinical Benchmark Antibodies and reference inhibitors included |
| False Positives | Validated siRNA included for specificity checks |
Live SQLE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SQLE therapeutics is intensifying, with major players shifting focus from traditional metabolic indications to oncology. SQLE (Squalene Monooxygenase) catalyzes the second rate-limiting step in cholesterol biosynthesis and has emerged as a key oncogene in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and hepatocellular carcinoma (HCC). As first-generation small-molecule inhibitors (such as Terbinafine derivatives) reach preclinical validation, the next wave of R&andD is targeting SQLE degradation via PROTACs and combination therapies to overcome metabolic rewiring in tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech startups | NASH, Hepatocellular Carcinoma | Enzymatic Activity Assay (Need soluble, active catalytic domain protein) |
| PROTACs / Degraders | Pharma / Degrader Specialists | Prostate Cancer, Breast Cancer | Ubiquitination & Degradation Assay (Need stable cell lines via Lentivirus) |
| Combination Therapies (w/ Statins) | Oncology Biotechs | Colorectal Cancer, Solid Tumors | Pathway readout validation (Need HMGCR and SREBP2 control reagents) |